Cellectar Biosciences, Inc.CLRBNASDAQ
Loading
Cash Flow Under PressureContracting
Percentile Rank21
Studio
Year-over-Year Change

Operating cash flow minus capital expenditures

Latest
$-23.12M
↓ 10% vs avg
Percentile
P21
Within normal range
Streak
1 yr
Consecutive growthContracting
Average
$-20.95M
Historical baseline
PeriodValueYoY Change
TTM$-23.12M+51.5%
2024$-47.69M-43.5%
2023$-33.24M-30.6%
2022$-25.45M-12.1%
2021$-22.71M-62.3%
2020$-14.00M-19.4%
2019$-11.72M+0.9%
2018$-11.83M-4.0%
2017$-11.37M-36.1%
2016$-8.35M-